Finance

Lists
CRNX:NASDAQ
Crinetics Pharmaceuticals Inc
$84.95
0.00%
(0.00) 1D
Aug 31, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRNX...
Mkt. cap
9.01B
Avg. vol.
2.68M
Volume
0.00
52-wk high
$85.01
52-wk low
$31.00
EPS
-$5.05
Beta
0.12
Shares outstanding
106.06M
No. of employees
594
Mkt. cap
9.01B
Avg. vol.
2.68M
Volume
0.00
52-wk high
$85.01
52-wk low
$31.00
EPS
-$5.05
Beta
0.12
Shares outstanding
106.06M
No. of employees
594
News stories
From web sources and news partners
Profile
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018. In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion. Wikipedia
About Crinetics Pharmaceuticals Inc
CEO-
Employees594
FoundedNov 18, 2008
Headquarters-
SectorPharmaceutical industry
Websitecrinetics.com
Analyst ratings
Based on 11 analysts giving stock ratings to CRNX in the past 3 months
Hold
Buy
2
Hold
9
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CRNX in the last 3 months.
Highest
Current $84.95
$95.00 (+11.83%)
Average
$85.56 (+0.72%)
Lowest
$80.00 (-5.83%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Hold
Reiterated
$85.00
+0.1%
08/11/2026
Ashwani Verma
UBS
Hold
Downgraded
$85.00
+0.1%
07/28/2026
Kate Dellorusso
LifeSci Capital
Hold
Maintained
$85.00
+0.1%
07/11/2026
Alex Thompson CFA
Stifel Nicolaus
Hold
Downgraded
$85.00
+0.1%
07/08/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Downgraded
$85.00
+0.1%
07/08/2026
Tyler Van Buren
TD Cowen
Hold
Downgraded
-
-
07/07/2026
Jonathan Wolleben
Citizens JMP
Hold
Downgraded
-
-
07/07/2026
Dennis Ding
Jefferies
Hold
Downgraded
$85.00
+0.1%
07/07/2026
Catherine Novack
JonesTrading
Hold
Downgraded
$85.00
+0.1%
07/07/2026
Yasmeen Rahimi
Piper Sandler
Hold
Downgraded
-
-
07/07/2026
Leland Gershell
Oppenheimer
Hold
Downgraded
-
-
07/07/2026
Joshua Schimmer
Cantor Fitzgerald
Hold
Downgraded
-
-
07/06/2026
So Youn Shim
UBS
Buy
Initiated
$55.00
-35.3%
07/02/2026
Maxwell Skor
Morgan Stanley
Buy
Maintained
$80.00
-5.8%
06/15/2026
Joseph Schwartz
Leerink Partners
Buy
Maintained
$95.00
+11.8%
06/11/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$67.00
-21.1%
03/01/2026
Last report
Aug 3, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.14 / -$1.18
+3.73%beat
Revenue / Est. (USD)
25.12M / 14.87M
+68.91%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
143.00K
6.16M
10.73M
25.12M
Cost of goods sold
90.46M
86.13M
100.28M
100.00M
Cost of revenue
90.46M
86.13M
100.28M
100.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
52.26M
53.70M
50.83M
57.57M
Operating expense
52.26M
53.70M
50.83M
57.57M
Total operating expenses
142.73M
139.83M
151.11M
157.58M
Operating income
-142.59M
-133.67M
-140.38M
-132.46M
Other non operating income
-49.00K
-125.00K
-131.00K
-423.00K
EBT including unusual items
-130.09M
-122.64M
-127.84M
-120.86M
EBT excluding unusual items
-130.09M
-122.64M
-127.84M
-120.86M
Income tax expense
-
180.00K
-
-
Effective tax rate
-
-0.15%
-
-
Other operating expenses
-
-
-
-
Net income
-130.09M
-122.82M
-127.84M
-120.86M
Net profit margin
-90,972.73%
-1,993.43%
-1,191.03%
-481.15%
Earnings per share
-1.38
-1.29
-1.23
-1.14
Interest and investment income
12.54M
11.16M
12.66M
12.03M
Interest expense
-
-
-
-
Net interest expenses
12.54M
11.16M
12.66M
12.03M
Depreciation and amortization charges
-
-
-
-
EBITDA
-141.57M
-132.67M
-139.22M
-131.39M
Gain or loss from assets sale
-
8.00K
20.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps